Auspex Pharmaceuticals (ASPX) SD-809 Results 'Stunning', BMO Capital Says; PT Raised to $60

BMO Capital analyst Jim Birchenough reiterated an Outperform rating and boosted his price target on Auspex Pharmaceuticals (NASDAQ: ASPX) to $60.00 (from $40.00) after the company announced positive top-line data from First-HD, the registrational study of its deuterated XENAZINE analog, SD-809, in patients with chorea associated with Huntington’s disease. Birchenough called the results "stunning."

Birchenough said, "Overall efficacy and tolerability results are better than expected and should support label differentiation from incumbent brand XENAZINE. With rates of neuropsychiatric effects well below that seen historically for XENAZINE we expect SD-809 to drive market expansion and command dominant market share."

For an analyst ratings summary and ratings history on Auspex Pharmaceuticals click here. For more ratings news on Auspex Pharmaceuticals click here.

Shares of Auspex Pharmaceuticals closed at $25.09 yesterday.

You May Also Be Interested In

• Boston Beer Company (SAM) PT Lowered to $325 at Jefferies
• Spotify (SPOT) PT Raised to $396 at Rosenblatt
• Halliburton (HAL) PT Raised to $52 at Wolfe Research